ReCode Therapeutics to Present Preclinical Data Using Proprietary SORT LNP Delivery Platform From Its mRNA-based Therapeutic Programs at the ATS 2022 International Conference in San Francisco

MENLO PARK, Calif. & DALLAS--(BUSINESS WIRE)-- #ATS2022--Preclinical data from ReCode Therapeutics mRNA-based therapeutic programs in cystic fibrosis and primary ciliary dyskinesia to be presented at ATS2022

Click to view original post